Minority outreach pairs docs, clergy

Share this article:
A triumvirate of companies is seeking pharma sponsors for a disease awareness campaign centered on Black churches.

The campaign, called the Minority Outreach Initiative and run by Healthy National Network, Roska Healthcare Advertising and Impact Health, would stage or promote health screenings at Black churches, with a focus on chronic diseases that impact African Americans disproportionately: diabetes, obesity, cancer, cardiovascular disease,   HIV/Aids and asthma. The effort would connect Black pastors and faith-based organizations with key physician opinion leaders in their communities, educating doctors, clergy and their parishoners alike on disease states.

Those testing as at-risk for a disease would receive on-the-spot counseling, with the option to set up a doctor’s appointment then and there and to enroll in relationship marketing programs. 

“It’s really convenient on a Sunday, when most people are there for services anyway,” says David Comey, founder and managing director of HNN.

The unbranded campaign would be promoted through the National Medical Association, an organization of Black physicians. “What we’re trying to do is to connect the dots,” says Jay Bolling, president of Roska. “Access in many of these communities is really fractured.” 
Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?